Separately, B. Riley set a $6.30 price objective on shares of Biomerica and gave the stock a “buy” rating in a report on Monday, October 21st.
NASDAQ:BMRA opened at $2.82 on Thursday. The company has a 50-day moving average of $2.98 and a 200-day moving average of $3.05. The company has a market capitalization of $30.26 million, a price-to-earnings ratio of -11.28 and a beta of 1.41. Biomerica has a 52 week low of $2.15 and a 52 week high of $3.69. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.17 and a current ratio of 2.27.
Biomerica (NASDAQ:BMRA) last released its quarterly earnings data on Wednesday, January 15th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.69 million. Biomerica had a negative net margin of 47.06% and a negative return on equity of 65.75%. Sell-side analysts forecast that Biomerica will post -0.24 EPS for the current year.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Further Reading: What is a stock buyback?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.